Merck KGaA (FRA:MRK) has been assigned a €85.00 ($104.94) target price by analysts at Deutsche Bank in a research note issued on Wednesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Deutsche Bank’s target price indicates a potential upside of 8.09% from the stock’s previous close.
Several other research analysts also recently weighed in on the company. Berenberg Bank set a €106.00 ($130.86) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Monday. UBS set a €115.00 ($141.98) target price on Merck KGaA and gave the company a “buy” rating in a research report on Wednesday, March 14th. Kepler Capital Markets set a €106.00 ($130.86) target price on Merck KGaA and gave the company a “buy” rating in a research report on Monday, March 12th. DZ Bank reiterated a “buy” rating on shares of Merck KGaA in a research report on Monday, March 12th. Finally, Nord/LB set a €84.00 ($103.70) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Monday, March 12th. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of €100.91 ($124.58).
MRK stock opened at €78.64 ($97.09) on Wednesday. Merck KGaA has a 52 week low of €76.60 ($94.57) and a 52 week high of €115.00 ($141.98). The firm has a market capitalization of $10,070.00 and a P/E ratio of 13.15.
COPYRIGHT VIOLATION WARNING: This story was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://transcriptdaily.com/2018/03/21/deutsche-bank-analysts-give-merck-kgaa-mrk-a-85-00-price-target.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.